Home > Insider Trading > Filing (0001209191-18-062473)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645460	Cue Biopharma Inc.	CUE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
897744	A Christopher Marlett	21 Erie Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-12	9,000	$5.09	9,000	No	4	P	Direct
Common Stock	Acquisiton	2018-12-12	3,189	$5.07	10,732	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,017,973	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.13, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.98 to $5.07, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4
Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee.
The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes.